Fig. 1 · Structure

Documents & Downloads

Exemestane

Cat. No. A10378 CAS 107868-30-4

Aromatase inhibitor

Exemestane is an oral steroidal aromatase inhibitor that is used in ER-positive breast cancer in addition to surgery and/or radiation in post-menopausal women.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Exemestane inhibits aromatase-dependent estrone formation. In a recombinant human CYP19A1 S9 assay, the reported IC50 was 1.3 ± 0.28 µM (mean ± SD; four independent experiments) with 5 µM androstenedione. Inhibition was also observed in pooled human ovarian S9 fractions. These are assay-specific biochemical results. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Aromatase (human) 30 nM
Aromatase (rat) 40 nM

Cellular Effect

Cell Line Activity Value Description Reference
MCF7 IC50 0.9 μM Inhibition of human placental microsome aromatase expressed in human MCF7 cells using [1beta-3H] androstenedione as substrate after 1 hr by liquid scintillation counting [PMID: 25277066]

Exemestane Research Summary

This section summarizes 4 in vitro studies of Exemestane from 2 published references. In vitro models include S9 fraction from HEK293 cells overexpressing wild-type human CYP19A1.

Exemestane In Vitro Studies

In testosterone-stimulated MCF-7aro breast cancer cells, micromolar exemestane reduced DNA synthesis and shifted cell-cycle distribution toward G0/G1 at 3 days and G2/M at 6 days. Viability effects depended on concentration and exposure time; the lower concentrations did not reduce viability until 9 days. [2]

In the same cell model, 10–15 µM exemestane increased the Annexin V-positive/7-AAD-negative fraction after 6 days. No Annexin V difference was reported after 3 days, indicating a delayed response under these conditions. [2]

Aromatase inhibition in recombinant-enzyme S9 fractions

Biochemical assay · S9 fraction from HEK293 cells overexpressing wild-type human CYP19A1 [1]

Parent exemestane inhibited estrone formation in a cell-free enzyme preparation. The reported potency depends on substrate concentration and assay design.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of aromatase-dependent estrone formationIC50 1.3 ± 0.28 µM (mean ± SD; four independent experiments per Table 1 footnote a)[1]
Estrone formation relative to no-inhibitor controlInhibition 51% at 1 µM; 87% at 10 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.01–30 µM for parent-drug IC50; screening at 1 and 10 µM
Exposure duration
45 minutes at 37°C; selected potency series without the 30-minute preincubation step
Method
Estrone formation quantified by UPLC-MS; 125 µg S9 protein, 5 µM androstenedione and NADPH-regeneration system in 50 µL
Vehicle
Final 1.2% methanol and 0.4% DMSO
Co-treatment
No therapeutic combination; other compounds were tested separately.
Reported limits
Chemical purity and lot-specific identity data are not supplied in the selected methods.
Methods and source locations

Compound reported in the paper: Exemestane; Compound label in the paper: EXE

Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.

Materials and Methods: Chemicals and Materials, Inhibition Assays of Aromatase Activity, IC50 and IC50 Shift Determinations, Data Analysis; Results paragraphs 1–3; Table 1 footnote a

Inhibition of aromatase-dependent estrone formation: UPLC-MS estrone assay; three-parameter concentration-response fitting — Table 1 EXE row and footnote a; Methods: IC50 determinations

Estrone formation relative to no-inhibitor control: 45-minute S9 assay; screening performed in triplicate experiments — Results first paragraph; Figure 1 caption; Methods: Inhibition Assays

Inhibition of estrone formation in human ovarian S9

Biochemical assay · Pooled S9 fractions from three normal human ovarian tissue donors, aged 30–40 years; ex vivo biochemical preparation [1]

Parent exemestane inhibited estrone formation in pooled human ovarian tissue S9. This is a tissue-enzyme assay, not treatment of women or an animal experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Estrone formation versus uninhibited assayInhibition 46% at 1 µM; 78% at 10 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 and 10 µM
Exposure duration
45 minutes at 37°C
Method
UPLC-MS estrone assay using 300 µg pooled ovarian S9 protein and 5 µM androstenedione; screening conditions otherwise as described for the enzyme assay
Vehicle
Final 1.2% methanol and 0.4% DMSO under the referenced assay conditions
Co-treatment
None; parent drug and metabolites screened separately.
Reported limits
Pooling prevents donor-level response estimates.
Methods and source locations

Compound reported in the paper: Exemestane; Compound label in the paper: EXE

Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.

Methods: Anti-aromatase Activity Determinations in Ovarian Tissue and Inhibition Assays; Results second paragraph; Figure 2 caption

Estrone formation versus uninhibited assay: UPLC-MS; triplicate experiments on pooled S9 (three donors) — Results ovarian-tissue paragraph; Figure 2 caption

Growth and cell-cycle effects in MCF-7aro cells

Cell-based study · ER-positive, aromatase-overexpressing MCF-7aro human breast cancer cells in steroid-depleted medium with 1 nM testosterone [2]

Exemestane reduced DNA synthesis and altered cell-cycle distribution, while viability effects depended on dose and exposure time.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
G0/G1 cell fraction after 3 daysPercentage of cells Control: 70.49±1.37%; 10 µM: 90.30±1.68% (p<0.001); mean ± SEM[2]
G2/M cell fraction after 6 daysPercentage of cells Control: 14.56±0.34%; 10 µM: 34.47±2.67% (p<0.001); mean ± SEM[2]
DNA synthesis, metabolic viability and membrane integrityQualitative dose/time response DNA synthesis decreased at tested concentrations at 3, 6 and 9 days. Results text reports no viability reduction after 2 days; 2.5–5 µM did not reduce viability except at 9 days. Significant LDH release occurred only at 15 µM after 9 days.[2]

Literature-Reported Treatment Conditions

Treatment concentration
2.5–15 µM for viability and DNA synthesis; 2.5–10 µM for cell-cycle analysis
Exposure duration
Viability: 2, 3, 6 and 9 days; DNA synthesis shown at 3, 6 and 9 days; cell cycle: 3 and 6 days; medium and drug refreshed every 3 days
Method
MTT, LDH release, tritiated-thymidine incorporation and PI flow cytometry
Vehicle
0.05% DMSO in the 1 nM testosterone control
Co-treatment
None; testosterone is assay substrate and proliferation stimulus.
Reported limits
No extrapolation to clinical exposure or all ER-positive breast cancer cells.
Methods and source locations

Compound reported in the paper: Exemestane; Compound label in the paper: exemestane

Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.

Results: Cell viability and cell proliferation; Cell cycle analysis; Figure 2A–E; Methods: Cell culture, Cell viability and cell proliferation, Cell cycle analysis, Statistical analysis

G0/G1 cell fraction after 3 days: PI flow cytometry; three independent experiments performed in triplicate — Results: Cell cycle analysis; Figure 2D and caption

G2/M cell fraction after 6 days: PI flow cytometry; three independent experiments performed in triplicate — Results: Cell cycle analysis; Figure 2E and caption

DNA synthesis, metabolic viability and membrane integrity: Thymidine incorporation, MTT and LDH assays — Results: Cell viability and cell proliferation; Figure 2A–C and caption

Delayed Annexin V response in MCF-7aro cells

Cell-based study · MCF-7aro cells with 1 nM testosterone; adherent and non-adherent cells pooled for flow analysis [2]

Exemestane increased the early-apoptotic Annexin V-positive/7-AAD-negative fraction after prolonged exposure. No difference was reported at 3 days.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Annexin V+/7-AAD− fraction after 6 daysPercentage of cells Control: 3.67±0.35%; 10 µM: 9.80±0.92% (p<0.01); 15 µM: 10.04±0.61% (p<0.001); mean ± SEM[2]
Annexin V response after 3 daysReported null finding No difference versus control (data not shown)[2]

Literature-Reported Treatment Conditions

Treatment concentration
5–15 µM
Exposure duration
3, 6 and 9 days; medium and drug refreshed every 3 days
Method
Annexin V-PE/7-AAD flow cytometry with testosterone/vehicle control and 1 µM staurosporine positive control (14 hours)
Vehicle
0.05% DMSO in shared control
Co-treatment
None in the selected experiment.
Reported limits
The 3-day null result is described as data not shown; no numerical estimate is available.
Methods and source locations

Compound reported in the paper: Exemestane; Compound label in the paper: exemestane

Compound-level evidence for the reported material and model; no validation of Adooq material, lot purity or formulation.

Results: Analysis of cell death, Annexin V paragraph; Table 1 and footnote; Methods: Cell culture and Analysis of apoptosis

Annexin V+/7-AAD− fraction after 6 days: Flow cytometry; three independent experiments done in triplicate — Table 1, 6 DAYS, Annexin V+/7-AAD− row and footnote

Annexin V response after 3 days: Annexin V-PE assay — Results: Analysis of cell death, first paragraph

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 107868-30-4
Applications Aromatase inhibitor
Formula C20H24O2
Molecular Weight 296.4
Synonyms Aromasin
SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 52 mg/mL (175.43 mM)
Water Insoluble
Ethanol 15 mg/mL (50.6 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Exemestane Research References

  1. [1] Irina Teslenko, Christy J.W. Watson, Gang Chen, et al. Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates Molecular Pharmacology (2022). PMID: 35953090 DOI: 10.1124/molpharm.122.000545 Source material
  2. [2] Cristina Amaral, Margarida Borges, Soraia Melo, et al. Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment PLoS ONE (2012). PMID: 22912703 DOI: 10.1371/journal.pone.0042398 Source material

Added to your cart

View Cart Checkout
Loading...